Toll样受体9配体CpG-ODN鼻内应用对变应性联合气道疾病炎性反应的影响

目的:探讨免疫刺激序列Cp G寡聚脱氧核苷酸(Cp G-ODN)鼻内应用与皮下注射对变应性联合气道疾病(ACAD)模型小鼠下气道炎性反应的影响。方法:30只清洁级雌性BALB/c鼠随机分为正常对照组(control组)、变应性鼻炎组(AR组)、变应性联合气道疾病组(ACAD组)、变应性联合气道疾病Cp G-ODN鼻内滴入组(Cp G i.n.组)和变应性联合气道疾病Cp G-ODN皮下注射组(Cp G i.d.组)。实验组动物依次进行腹腔卵白蛋白(OVA)和氢氧化铝凝胶基础致敏和3次鼻腔激发,此后OVA或生理盐水(NS)雾化气道激发,正常对照组则给予NS。Cp G i.n.组和Cp G i.d.组分别给予10.0μg Cp G-ODN滴鼻和皮下注射,其它组给予NS滴鼻或皮下注射。观察Cp GODN干预后对鼻腔及下气道病理变化及评分,并对支气管肺泡灌洗液(BALF)行白细胞分类及嗜酸性粒细胞计数,ELISA法测定BALF和脾脏中细胞因子IL-4、IL-5、IL-13和IFN-γ,以及血清OVA特异性Ig E。结果:炎症细胞浸润评分示ACAD组小鼠肺部的病理改变程度高于control组和AR组(P0.01);Cp G i.n.组炎症评分较ACAD组下降,差异有统计学显著性(P0.05),而Cp G i.d.组炎症评分较ACAD组略有下降,但差异无统计学意义。Cp G i.n.组BALF中的白细胞总数、EOS绝对值计数、EOS百分比、BALF和脾脏淋巴细胞上清液中Th2细胞因子较ACAD组降低,差异具有统计学显著性(P0.01)。Cp G i.d.组上述指标略低于ACAD组,但差异无统计学显著性。Cp G i.n.组血清的OVA特异性Ig E较ACAD组下降,差异有统计学显著性(P0.05),而Cp G i.d.组与ACAD组比较有所下降,但差异无统计学显著性。结论:Cp G-ODN可通过抑制变应性鼻炎而抑制变应性联合气道疾病小鼠的下气道炎性反应,鼻内应用可能较皮下注射更有效。

Effect of intranasal treatment with Toll-like receptor 9 ligand CpG oligodeoxynucleotides on airway inflammation in mice with allergic combined airway disease

AIM: To investigate the therapeutic effect of intranasal administration of CpG oligodeoxynucleotides (CpG-ODN), compared with intradermal administration, on lower airway inflammation in ovalbumin (OVA)-induced allergic combined airway disease (ACAD) mouse model.METHODS: Totally 30 female BALB/c mice aged from 6 to 8 weeks were randomly divided into control group, allergic rhinitis model group (AR group), ACAD group, ACAD intranasally treated with CpG-ODN group (CpG i.n. group) and ACAD intradermally treated with CpG-ODN group (CpG i.d. group). The mice were sensitized and challenged with OVA. Treatment with CpG-ODN was also performed during challenge, either intranasally or intradermally. Immunologic variables and nasal symptom were studied.RESULTS: Compared with CpG i.d. group and ACAD group, the percentage of eosinophils from bronchoalveolar lavage fluid (BALF), the levels of Th2 cytokine production in BALF and supernatants of cultured splenic lymphocytes, OVA-specific IgE from blood, peribronchial inflammation score in the lung, and nasal symptoms were significantly reduced in CpG i.n. group.CONCLUSION: Allergic rhinitis treated by CpG-ODN has a significant improvement on lower airway inflammation in ACAD mouse model; and it may be more effective when administrated intranasally than intradermally.